ArticleCancer innovation2025
Global, Regional, and National Burden of Breast Cancer in Adolescents and Young Adults Aged 15-39 Years From 1990 to 2021 Based on the Global Burden of Disease Study 2021.
Article in Cancer innovation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Decoding age-stratified clinical and molecular heterogeneity in male breast cancer through multiomic profiling.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Machine learning-driven drug repurposing for HER2-positive breast cancer.Scientific reports · 2026Article
- A fusion-deletion genomic-event underlies poor prognosis in young patients with luminal breast cancer.PloS one · 2026Article
- Macrophage-associated prognostic modeling uncovers immunotherapy response mechanisms and defines HAGHL as a novel oncogenic driver in breast cancer.Frontiers in immunology · 2026Article
- Identification of endogenous reference genes for RT-qPCR analysis in breast cancer and matched adjacent tissues.Frontiers in oncology · 2025Article
- Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) remains a significant global public health challenge, and its incidence and mortality rates among adolescents and young adults (AYAs) aged 15-39 years are increasing. Compared with older adults, AYAs often face poorer prognoses and a higher disease burden. Understanding the trends and determinants of BC burden in AYAs is crucial for guiding preventive measures, early detection programs, and treatment strategies. The aim of this study is to systematically investigate the trends and distribution of the BC burden among AYAs aged 15-39 years across regions and countries and identify the contributing risk factors and disparities in incidence, mortality, and disability-adjusted life years (DALYs). Methods: Data on BC were collected from the Global Burden of Disease (GBD) 2021 database. The number of cases, age-standardized rates, mortality, and DALYs for BC were assessed for 204 countries and territories from 1990 to 2021. Joinpoint regression analysis was used to calculate the average annual percentage changes (AAPCs) in incidence, mortality, and DALYs. Risk factors that contribute to the BC burden were also evaluated. Results: According to GBD 2021 estimates, 180,791 new BC cases and 42,055 related deaths were observed among AYAs globally. Between 1990 and 2021, the global incidence rate increased by 33.4%, with the highest incidence observed in regions with a high sociodemographic index (SDI) and the highest mortality rates in low-SDI regions. Incidence rates in women showed a significant upward trend (AAPC, 3.03) and peaked in North Africa and the Middle East, whereas the most rapid increase in incidence in men was noted in East Asia (AAPC, 4.87). Projections indicated a decline in age-standardized incidence rates across most European countries by 2050, in contrast to rising trends in Asia and Africa. Risk factor analysis identified dietary risks (10.5%), tobacco smoking (2%), and high fasting plasma glucose (1.6%) as major contributors to DALYs. Conclusions: The global burden of AYA BC has increased significantly, particularly in regions with a middle and low SDI. The findings highlight the need for targeted preventive interventions for high-risk populations and provide critical insights for developing regional control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.